Aeovian is a clinical-stage biotherapeutics company developing mTORC1-specific inhibitors. Its lead asset, AV078, is entering a Phase 2 study for TSC-associated refractory epilepsy, a pediatric genetic disease caused by dysregulation of the mTOR pathway
Neurology
CTI LSF III
Lead
Director & Observer
October 6, 2025
Active
Series B
Aeovian Pharmaceutical is developing a first-in-class brain penetrant mTORC1-specific inhibitor with a unique balance of specificity and potency. Its lead asset is being studied for a debilitating rare pediatric neurological disorder but also has broad potential in other indications
December 16, 2025
